We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
-4.8%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$724M
AUM Growth
+$565M
(+356%)
Cap. Flow
+$651M
Cap. Flow
% of AUM
90.01%
Top 10 Holdings %
Top 10 Hldgs %
43.31%
Holding
66
New
33
Increased
17
Reduced
2
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$64.2M |
| 2 |
Merck
MRK
|
+$40.5M |
| 3 |
McKesson
MCK
|
+$35.6M |
| 4 |
AbbVie
ABBV
|
+$32.6M |
| 5 |
Cardinal Health
CAH
|
+$26.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$13.8M |
| 2 |
HCA Healthcare
HCA
|
+$9.27M |
| 3 |
Zimmer Biomet
ZBH
|
+$8.16M |
| 4 |
Edwards Lifesciences
EW
|
+$6.3M |
| 5 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
+$5.76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
uniQure
QURE
$2.75B
| $11.2M | 1.55% |
237,000
+182,000
| +331% | +$10.5M |
|
27
Moderna
MRNA
$21.6B
| $10.9M | 1.51% |
+365,000
| New | +$8.4M |
|
28
Humana
HUM
$43.9B
| $10.4M | 1.43% |
+33,000
| New | +$11.1M |
|
|
HZNP
29
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $9.86M | 1.36% |
333,000
+183,000
| +122% | +$6.19M |
|
|
CCXI
30
DELISTED
ChemoCentryx, Inc.
CCXI
| $9.48M | 1.31% |
+236,000
| New | +$10M |
|
31
Neurocrine Biosciences
NBIX
$18.2B
| $8.48M | 1.17% |
98,000
+65,000
| +197% | +$6.36M |
|
32
Vertex Pharmaceuticals
VRTX
$123B
| $8.09M | 1.12% |
34,000
-6,000
| -15% | -$1.38M |
|
33
Sarepta Therapeutics
SRPT
$1.64B
| $7.83M | 1.08% |
+80,000
| New | +$9.14M |
|
34
Ligand Pharmaceuticals
LGND
$5.77B
| $7.42M | 1.03% |
+163,506
| New | +$9.27M |
|
35
Ironwood Pharmaceuticals
IRWD
$586M
| $7.42M | 1.02% |
+735,000
| New | +$8.64M |
|
36
Verastem
VSTM
$528M
| $7.37M | 1.02% |
+232,558
| New | +$5.83M |
|
37
Charles River Laboratories
CRL
$11.3B
| $7.19M | 0.99% |
+57,000
| New | +$8.55M |
|
|
AGN
38
DELISTED
Allergan plc
AGN
| $7.08M | 0.98% |
+40,000
| New | +$7.53M |
|
|
AERI
39
DELISTED
Aerie Pharmaceuticals
AERI
| $6.84M | 0.95% |
+507,000
| New | +$9.62M |
|
40
Ascendis Pharma A/S
ASND
$16.5B
| $6.76M | 0.93% |
60,000
+17,900
| +43% | +$2.33M |
|
|
IMMU
41
DELISTED
Immunomedics Inc
IMMU
| $6.65M | 0.92% |
493,000
+353,000
| +252% | +$5.94M |
|
|
AMRN
42
CALL
Amarin Corp
AMRN
$297M
| $6.5M | 0.9% |
+81,240
| New | +$27M |
|
|
ESPR
43
DELISTED
Esperion Therapeutics
ESPR
| $6.46M | 0.89% |
205,000
+74,600
| +57% | +$3.94M |
|
44
Coherus Oncology
CHRS
$217M
| $6.2M | 0.86% |
382,000
+167,500
| +78% | +$3.09M |
|
45
CALL
Minerva Neurosciences
NERV
$191M
| $5.96M | 0.82% |
+123,750
| New | +$7.47M |
|
|
AIMT
46
DELISTED
Aimmune Therapeutics
AIMT
| $5.88M | 0.81% |
+408,000
| New | +$10.4M |
|
47
Anika Therapeutics
ANIK
$215M
| $4.86M | 0.67% |
+168,000
| New | +$6.8M |
|
48
BioXcel Therapeutics
BTAI
$24.8M
| $4.72M | 0.65% |
+13,188
| New | +$4.74M |
|
|
AVDL
49
DELISTED
Avadel Pharmaceuticals
AVDL
| $3.03M | 0.42% |
+382,000
| New | +$2.93M |
|
|
50
Minerva Neurosciences
NERV
$191M
| $2.67M | 0.37% |
+55,525
| New | +$3.35M |
|
Similar funds
NM
PWAM
LJAC
NI
MCM
TS
TW
PGA
Avidity Partners Management's Q1 2020 Portfolio in Review
As of Q1 2020, Avidity Partners Management held 66 positions worth $724M, up 356% from $159M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Avidity Partners Management deployed $651M of net new capital in Q1 2020, opening 33 new positions and adding to 17 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 580,000 shares worth $66.9M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 98% a quarter earlier.
On the sell side, the largest reduction was Collegium Pharmaceutical, an estimated $3.36M trimmed.
- Avidity Partners Management's largest Q1 2020 buy was Seagen Inc. Common Stock: 580,000 shares worth $66.9M.
- Avidity Partners Management added most to AbbVie in Q1 2020, an estimated $32.6M increase.
- Avidity Partners Management's biggest Q1 2020 reduction was Collegium Pharmaceutical, cutting an estimated $3.36M.
- Avidity Partners Management fully exited Baxter International in Q1 2020, selling an estimated $13.8M.
- Avidity Partners Management's ten largest holdings make up 43% of its $724M portfolio in Q1 2020.
- Avidity Partners Management opened 33 new positions and closed 14 in Q1 2020.
- Avidity Partners Management's portfolio value rose 356% quarter-over-quarter to $724M.
Based on Avidity Partners Management's 13F filing for Q1 2020, filed 15 May 2020.